Jpmorgan Chase & CO Black Diamond Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 17,574 shares of BDTX stock, worth $43,759. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,574
Previous 15,917
10.41%
Holding current value
$43,759
Previous $74,000
2.7%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding BDTX
# of Institutions
117Shares Held
48.8MCall Options Held
1.84MPut Options Held
1.93M-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.7MShares$26.7 Million0.03% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$21.2 Million0.62% of portfolio
-
Vestal Point Capital, LP New York, NY5.03MShares$12.5 Million1.66% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$11.1 Million1.48% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$8.01 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $90.5M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...